Fennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on Thursday

Fennec Pharmaceuticals (NASDAQ:FENC) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $16.42 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Fennec Pharmaceuticals Trading Up 1.6 %

NASDAQ:FENC opened at $6.50 on Thursday. The company’s 50-day moving average price is $6.39 and its 200-day moving average price is $5.63. The company has a market cap of $179.15 million, a P/E ratio of -64.99 and a beta of 0.36. Fennec Pharmaceuticals has a twelve month low of $3.96 and a twelve month high of $11.49.

Insider Buying and Selling

In related news, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total transaction of $66,600.00. Following the completion of the sale, the director now directly owns 76,294 shares in the company, valued at approximately $508,118.04. This trade represents a 11.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 31,186 shares of company stock worth $203,389. Insiders own 10.98% of the company’s stock.

Analysts Set New Price Targets

FENC has been the topic of several research reports. Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.